"Sandoz will be the leading biosimilars company in 2012," says Visiongain

Sandoz, the generics unit of Swiss drug major Novartis (NVN: VX), will retain its position as the global leader in the biosimilar drugs market in 2012. In that year, its three follow-on biologics will achieve $308 million in revenue, according to a new report from Visiongain.

Combined revenue for the top three companies in that market will expand with a compound annual growth rate (CAGR) of close to 25% between 2011 and 2016, notes the report, titled Pharma Leader Series: Top 25 Biosimilar Drug Manufacturers 2012-2022.   ,

Visiongain's analysis indicates that, in 2011, the top 10 biosimilar drug manufacturers accounted for 54.8% of that market. Global generics manufacturers occupied three of the top four places in the ranking. Leading manufacturers based in India, China and South Korea were also among the top 10 biosimilar manufacturers. All companies among the top 25 will experience revenue growth in the coming 10 years, although most will have market share fall.